Pharmacy Pearls: Medication Highlight – Mounjaro

Pharmacy Pearls: Medication Highlight – Mounjaro

November 7th, 2022 | Pharmacy PearlsDiabetes
In this edition of Pharmacy Pearls, you will find information about the new medication approved for treating type 2 diabetes in adults, tirzepatide (Mounjaro®). It has a novel mechanism of action as it is a dual GLP-1 and GIP agonist and has shown impressive clinical trial results in A1c reduction and weight loss. Ongoing studies, including a CV outcomes trial, will further inform its place in therapy, but it remains an exciting potential treatment option.
Cost and insurance coverage can be tricky for this agent; patients often need to have tried and failed several agents first, and even then, cost can be prohibitive. For those with commercial insurance, there is a manufacturer coupon available to reduce the cost found here.
As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.
Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download PDF [184.57 KB]